Added to YB: 2025-04-16
Pitch date: 2025-04-14
NVO [bullish]
Novo Nordisk A/S
-22.95%
current return
Author Info
FluentInQuality invests in high-quality businesses that generate steady and sustainable cashflows, proven track records, and the potential to act as a true compounding machines over the long run. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 65.12
Price Target
N/A
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
value
3 Undervalued High-Quality Stocks You Can Not Afford To Miss - Novo Nordisk A/S
NVO: Dominates global diabetes/obesity markets (30%+ insulin share, leading GLP-1 drugs Ozempic/Wegovy). Expanding into cardiovascular, kidney, Alzheimer's, addiction treatments. Strong financials: 40%+ operating margins, 60-70% ROIC, minimal debt. Resilient model with recurring revenue, global presence. TAM growing with 1B+ obese patients worldwide.
Read full article (2 min)